Nelson F, Lebrun-Frénay C, Boyko A, et al. Long-term outcomes in patients with progressive forms of relapsing MS treated with teriflunomide: real-world evidence. AAN 2018, S8.004.
‘Antisense’-oligonucleotide HTTRx verlaagt concentratie gemuteerd huntingtine
sep 2019 | Bewegingsstoornissen